Prevalence of tigecycline resistance in methicillin-resistant Staphylococcus aureus: a systematic review and meta-analysis.

Tigecycline (TG) is one of the newest antimicrobial drugs used in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. The TG Resistance Evaluation and Monitoring Test (T.E.S.T.) is a global surveillance study aimed at monitoring bacterial resistance to TG in MRSA. This study will provide comprehensive data on the activity of TG against MRSA strains across the world by 2022. An electronic search was conducted for articles published during 1997 to 2022 in Pubmed/Medline (n = 361), Scopus (n = 1735) and Web of science (n = 439) for the following keywords: ((Tygacil [Title/Abstract]) OR (Tigecycline [Title/Abstract])) AND (((Staphylococcus aureus [Title/Abstract]) OR (Methicillin resistant Staphylococcus aureus [Title/Abstract])) OR (MRSA [Title/Abstract])). The titles and abstracts of 2535 articles were screened and 48 publications that fulfilled the inclusion criteria were included. From all studies, 35 studies had a cross-sectional design, 11 studies were cohort and 2 studies were case control. Blood and respiratory tract were the main specimen source in MRSA. Meta-analysis showed the proportion of TG resistance is more than 0.004. The region (countries, continent), study type and detection method were examined as the contributing factors of heterogeneity among the studies. Microbial resistance to this antibiotic has been reported to be low, but this does not mean that it can be used widely and without supervision, but the resistance caused by it in MRSA and other pathogens should be carefully and regularly evaluated.